FDA
-
-
-
-
-
-
-
Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation
-
-
-
-
-
-
-
Pulse Biosciences gets FDA approval for atrial fibrillation device study
-
-
-
-
-
-
-
Pulse Biosciences (PLSE) Appoints Paul LaViolette as Chief Executive Officer
-
-
-
-
-
-
-
Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System
-
-
-
-
-
-
-
Pulse Biosciences (PLSE) Receives FDA 510(k) Clearance for its CellFX nsPFA Percutaneous Electrode System
-
-
-
-
-
-
-
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Percutaneous Electrode
-
-
-
-
-
-
-
Pulse Biosciences Announces Positive Clinical Data on Nano-Pulse Stimulation Procedure for Low-Risk Basal Cell Carcinoma Lesions
-
322,725 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

